Insider · CIK 0001679129

PRASAD SUYASH

Reports to the SEC for 2 companies · SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001679129

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-07-06	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−8,956 sh	$3.79	−$33.9K	530,589
2022-07-05	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−3,905 sh	$3.51	−$13.7K	539,545
2022-07-01	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−23.9K sh	$3.53	−$84.4K	543,450
2022-06-30	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−13.9K sh	$3.72	−$51.7K	567,373
2022-06-29	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−12.3K sh	$3.81	−$47K	581,265
2022-04-06	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	CMO and Head of R&D	AAward	+40.3K sh	—	—	40,325
2022-02-23	TSHATaysha Gene Therapies, Inc. · Employee Stock Option (right to buy)A Award	CMO and Head of R&D	AAward	+80.7K sh	—	—	80,650
2021-07-01	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−19.7K sh	$21.12	−$416K	593,589
2021-06-30	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−13.4K sh	$21.42	−$286K	619,997
2021-06-30	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−6,202 sh	$22.44	−$139K	613,795
2021-06-30	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−500 sh	$23.70	−$11.9K	613,295
2021-06-29	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−300 sh	$25.19	−$7,557	633,371
2021-06-29	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−3,862 sh	$24.46	−$94.5K	633,671
2021-06-29	TSHATaysha Gene Therapies, Inc.S Sale	CMO and Head of R&D	SSale	−35.1K sh	$23.74	−$832K	637,533
2021-01-19	TSHATaysha Gene Therapies, Inc. · Stock Option (Right to Buy)A Award	CMO and Head of R&D	AAward	+80K sh	—	—	80,000
2020-09-28	TSHATaysha Gene Therapies, Inc. · Series B Preferred StockC Conversion	CMO and Head of R&D	CConversion	−3,529 sh	—	—	0
2020-09-28	TSHATaysha Gene Therapies, Inc.C Conversion	CMO and Head of R&D	CConversion	+3,844 sh	—	—	672,589
2020-09-23	TSHATaysha Gene Therapies, Inc.A Award	CMO and Head of R&D	AAward	+669K sh	—	—	668,745
2019-06-05	Audentes Therapeutics, Inc.F Tax Payment	Senior VP & Chief Med Officer	FTax Payment	−757 sh	$37.31	−$28.2K	17,479
2019-05-13	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+10K sh	$0.79	+$7,900	28,236
2019-05-13	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−9,946 sh	$36.98	−$368K	18,290
2019-05-13	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−54 sh	$37.72	−$2,036.88	18,236
2019-05-13	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−10K sh	—	—	30,870
2019-02-25	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−10K sh	$30.06	−$301K	18,236
2019-02-25	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+10K sh	$0.79	+$7,900	28,236
2019-02-25	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−10K sh	—	—	40,870
2019-02-06	Audentes Therapeutics, Inc.Stock Option (right to buy)A Award	Senior VP & Chief Med Officer	AAward	+48.8K sh	—	—	48,750
2019-02-06	Audentes Therapeutics, Inc.A Award	Senior VP & Chief Med Officer	AAward	+17.5K sh	—	—	18,236
2018-11-15	Audentes Therapeutics, Inc.A Award	Senior VP & Chief Med Officer	AAward	+736 sh	$19.64	+$14.5K	736
2018-10-01	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−4,699 sh	$35.60	−$167K	0
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+100 sh	$0.79	+$79	100
2018-10-01	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−100 sh	$39.52	−$3,952	0
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+1,101 sh	$0.79	+$869.79	1,101
2018-10-01	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−1,101 sh	$38.85	−$42.8K	0
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+3,900 sh	$0.79	+$3,081	3,900
2018-10-01	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−3,900 sh	$37.82	−$148K	0
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+200 sh	$0.79	+$158	200
2018-10-01	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−200 sh	$36.31	−$7,263	0
2018-10-01	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+4,699 sh	$0.79	+$3,712.21	4,699
2018-10-01	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−10K sh	—	—	50,870
2018-07-02	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−4,989 sh	—	—	65,881
2018-07-02	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−4,989 sh	$38.02	−$190K	0
2018-07-02	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+5,011 sh	$0.79	+$3,958.69	5,011
2018-07-02	Audentes Therapeutics, Inc.S Sale	Senior VP & Chief Med Officer	SSale	−5,011 sh	$38.79	−$194K	0
2018-07-02	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−5,011 sh	—	—	60,870
2018-07-02	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+4,989 sh	$0.79	+$3,941.31	4,989
2018-03-29	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+7,800 sh	$0.79	+$6,162	7,800
2018-03-29	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−7,800 sh	—	—	70,870
2018-03-27	Audentes Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	−300 sh	—	—	78,670
2018-03-27	Audentes Therapeutics, Inc.M Exercise/Conversion	Senior VP & Chief Med Officer	MExercise/Conversion	+300 sh	$0.79	+$237	300

Recent filings

Accepted (ET)
Jul 74
PRASAD SUYASH0001209191-22-041455
SEC(opens sec.gov)
Jul 14
PRASAD SUYASH0001209191-22-040356
SEC(opens sec.gov)
Apr 84
PRASAD SUYASH0001209191-22-023862
SEC(opens sec.gov)
Feb 254
PRASAD SUYASH0001209191-22-013163
SEC(opens sec.gov)
Jul 14
PRASAD SUYASH0001209191-21-044563
SEC(opens sec.gov)
Jan 204
PRASAD SUYASH0001209191-21-004572
SEC(opens sec.gov)
Sep 304
PRASAD SUYASH0001209191-20-052463
SEC(opens sec.gov)
Sep 254
PRASAD SUYASH0001209191-20-052116
SEC(opens sec.gov)
Jun 74
PRASAD SUYASH0001209191-19-035588
SEC(opens sec.gov)
May 154
PRASAD SUYASH0001209191-19-030040
SEC(opens sec.gov)

Companies

Address

C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR

SAN FRANCISCO, CA, 94108